New hope for ulcerative colitis: experimental drug JNJ-78934804 enters final testing phase
NCT ID NCT07577856
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether the experimental drug JNJ-78934804 can help people with moderate to severe ulcerative colitis achieve remission better than the existing drug guselkumab. About 644 participants will receive either the new drug or guselkumab, and researchers will check at 48 weeks how many have no symptoms and healed gut lining. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-78934804 (an experimental drug) compared to guselkumab (TREMFYA)
What this could lead to
If successful, this could provide a new treatment option for people with moderate to severe ulcerative colitis, potentially helping more patients achieve remission.
What could go wrong
This is a phase 3 trial, but the experimental drug is still unproven. It may not work better than the existing drug guselkumab, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinnova Research
RECRUITINGAnaheim, California, 92805, United States
-
GCP Clinical Research
RECRUITINGTampa, Florida, 33609, United States
-
Kagoshima IBD Gastroenterology Clinic
RECRUITINGKagoshima, 892-0843, Japan
-
New York Gastroenterology Associates
RECRUITINGNew York, New York, 10075, United States
-
Peak Gastroenterology Associates
RECRUITINGColorado Springs, Colorado, 80907, United States
-
Southern Star Research Institute, LLC
RECRUITINGSan Antonio, Texas, 78229, United States